Skip to content
Screener

Evolus EOLS Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

AbbVie logo
AbbVieABBV
——

Other financials

Income statement

See full
Revenue$84.1M+21.2%
Gross profit$57.2M+26.2%
Operating income-$4.5M+55.5%
Net income-$8.1M+53.0%
EPS (diluted)-$0.12+55.6%

Balance sheet

See full
Cash & equivalents$45.2M-26.8%
Total debt$164.8M+12.3%
Total equity-$30.9M-65.7%
Total assets$248.0M+8.4%

Cash flow

See full
Operating cash flow-$3.6M+85.5%
CapEx$50.0K-92.7%
Free cash flow-$3.6M+85.7%

Valuation

See full
Market cap$501.32M+31.0%
Enterprise value$620.96M+32.8%
P/S1.6×+0.2×

Profitability

See full
Gross margin66.7%-0.4pp
Operating margin-13.7%-1.9pp
Net margin-10.9%-3.7pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×—
Current ratio1.7×-0.6×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The source filing: Evolus’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:56 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053468
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Amortization of operating lease right-of-use assets697572
Amortization of debt discount and issuance costs765610
Deferred income taxes(589)15
Revaluation of contingent royalty obligation payable to Evolus Founders1,236(1,763)
Other adjustments to operating activities304480
Changes in operating assets and liabilities:
Inventories5,048(4,291)
Accounts receivable(8,787)(1,781)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Evolus's contingent consideration fair value adjustments?
Evolus (EOLS) reported contingent consideration fair value adjustments of $1.25M in Q2 2026.
How has Evolus's contingent consideration fair value adjustments changed year-over-year?
Evolus's contingent consideration fair value adjustments increased by 131.9% year-over-year, from -$3.91M to $1.25M.
What is the long-term trend for Evolus's contingent consideration fair value adjustments?
Over 3 years (2021 to 2025), Evolus's contingent consideration fair value adjustments has grown at a 0.5% compound annual growth rate (CAGR), from $6.29M to -$6.38M.
What does contingent consideration fair value adjustments mean?
Contingent consideration fair value adjustments

Ask your AI about Evolus's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude